CN114456262B - Anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1 and application thereof in detection - Google Patents
Anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1 and application thereof in detection Download PDFInfo
- Publication number
- CN114456262B CN114456262B CN202210045301.0A CN202210045301A CN114456262B CN 114456262 B CN114456262 B CN 114456262B CN 202210045301 A CN202210045301 A CN 202210045301A CN 114456262 B CN114456262 B CN 114456262B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- influenza virus
- zju
- antibody
- nucleoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000011931 Nucleoproteins Human genes 0.000 title claims abstract description 34
- 108010061100 Nucleoproteins Proteins 0.000 title claims abstract description 34
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 34
- 206010069767 H1N1 influenza Diseases 0.000 title claims abstract description 30
- 201000010740 swine influenza Diseases 0.000 title claims abstract description 30
- 238000001514 detection method Methods 0.000 title claims abstract description 23
- 238000002965 ELISA Methods 0.000 claims abstract description 10
- 239000000427 antigen Substances 0.000 claims abstract description 5
- 102000036639 antigens Human genes 0.000 claims abstract description 5
- 108091007433 antigens Proteins 0.000 claims abstract description 5
- 238000010166 immunofluorescence Methods 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 238000002360 preparation method Methods 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 20
- 238000005516 engineering process Methods 0.000 abstract description 7
- 238000004458 analytical method Methods 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 45
- 210000004408 hybridoma Anatomy 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000005406 washing Methods 0.000 description 14
- 206010003445 Ascites Diseases 0.000 description 11
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 239000008055 phosphate buffer solution Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 8
- 201000000050 myeloid neoplasm Diseases 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 239000012228 culture supernatant Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 6
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 230000007910 cell fusion Effects 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000001261 affinity purification Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000018297 Immunoglobulin subtype Human genes 0.000 description 2
- 108050007411 Immunoglobulin subtype Proteins 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WRUWXBBEFUTJOU-XGEHTFHBSA-N Thr-Met-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N)O WRUWXBBEFUTJOU-XGEHTFHBSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- VNFSAYFQLXPHPY-CIQUZCHMSA-N Ala-Thr-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNFSAYFQLXPHPY-CIQUZCHMSA-N 0.000 description 1
- LEFKSBYHUGUWLP-ACZMJKKPSA-N Asn-Ala-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LEFKSBYHUGUWLP-ACZMJKKPSA-N 0.000 description 1
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 1
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 1
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 1
- GFYOIYJJMSHLSN-QXEWZRGKSA-N Asp-Val-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GFYOIYJJMSHLSN-QXEWZRGKSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- NIXHTNJAGGFBAW-CIUDSAMLSA-N Cys-Lys-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N NIXHTNJAGGFBAW-CIUDSAMLSA-N 0.000 description 1
- VLOLPWWCNKWRNB-LOKLDPHHSA-N Gln-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O VLOLPWWCNKWRNB-LOKLDPHHSA-N 0.000 description 1
- WVTIBGWZUMJBFY-GUBZILKMSA-N Glu-His-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O WVTIBGWZUMJBFY-GUBZILKMSA-N 0.000 description 1
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 description 1
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 1
- WJZLEENECIOOSA-WDSKDSINSA-N Gly-Asn-Gln Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O WJZLEENECIOOSA-WDSKDSINSA-N 0.000 description 1
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- FAELBUXXFQLUAX-AJNGGQMLSA-N Leu-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C FAELBUXXFQLUAX-AJNGGQMLSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- PXHCFKXNSBJSTQ-KKUMJFAQSA-N Lys-Asn-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)O PXHCFKXNSBJSTQ-KKUMJFAQSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 1
- BSKMOCNNLNDIMU-CDMKHQONSA-N Phe-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O BSKMOCNNLNDIMU-CDMKHQONSA-N 0.000 description 1
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 1
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 1
- JARJPEMLQAWNBR-GUBZILKMSA-N Pro-Asp-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JARJPEMLQAWNBR-GUBZILKMSA-N 0.000 description 1
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 description 1
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- UGTZYIPOBYXWRW-SRVKXCTJSA-N Ser-Phe-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O UGTZYIPOBYXWRW-SRVKXCTJSA-N 0.000 description 1
- DINQYZRMXGWWTG-GUBZILKMSA-N Ser-Pro-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DINQYZRMXGWWTG-GUBZILKMSA-N 0.000 description 1
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 1
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 1
- GFDUZZACIWNMPE-KZVJFYERSA-N Thr-Ala-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O GFDUZZACIWNMPE-KZVJFYERSA-N 0.000 description 1
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- MEBDIIKMUUNBSB-RPTUDFQQSA-N Thr-Phe-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MEBDIIKMUUNBSB-RPTUDFQQSA-N 0.000 description 1
- BGWSLEYVITZIQP-DCPHZVHLSA-N Trp-Phe-Ala Chemical compound C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(O)=O BGWSLEYVITZIQP-DCPHZVHLSA-N 0.000 description 1
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 description 1
- VPEFOFYNHBWFNQ-UFYCRDLUSA-N Tyr-Pro-Tyr Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 VPEFOFYNHBWFNQ-UFYCRDLUSA-N 0.000 description 1
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- QPPZEDOTPZOSEC-RCWTZXSCSA-N Val-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](C(C)C)N)O QPPZEDOTPZOSEC-RCWTZXSCSA-N 0.000 description 1
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides an anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1 and application thereof in detection. An anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1, wherein the subtype of the monoclonal antibody is IgG2a and kappa type, and can be specifically combined with influenza virus nucleoprotein antigen. The heavy chain amino acid sequence of the antibody is shown as SEQ ID No.2, and the light chain amino acid sequence is shown as SEQ ID No. 4. Further physical and chemical property analysis and identification are carried out on the monoclonal antibody, and a method for detecting H1N1 nucleoprotein by the monoclonal antibody through immunofluorescence and enzyme-linked immunosorbent assay is established. The invention provides an effective tool for the auxiliary diagnosis of H1N1 influenza virus infection in clinical samples, and can be popularized and applied to various detection technologies and clinical and experimental researches.
Description
Technical Field
The invention belongs to the field of biotechnology, and relates to preparation and application of an anti-H1N 1 influenza virus nucleoprotein monoclonal antibody, which are characterized in that a hybridoma cell line secreting the anti-nucleoprotein monoclonal antibody is obtained by utilizing cell engineering and antibody engineering technologies, ascites is induced by mice of the same strain, the anti-nucleoprotein monoclonal antibody ZJU-NP-A1 is prepared, identified as IgG2a and kappa type, and the application of the antibody is realized by utilizing affinity purification, electrophoresis, immunization and other technologies.
Background
Since 2009 influenza A H1N1 outbreak, the influenza A H1N1 has become a main influenza virus strain in China in the world, is an epidemic situation which is advocated by international organizations such as WHO and FDA and is controlled together in the world, and the influenza A H1N1 is easy to develop into severe cases after infection, thereby causing serious threat to the life health of human beings. Current methods of treating H1N1 influenza are mainly neuraminidase inhibitors (oseltamivir). Early treatment becomes critical and the risk of death increases when antiviral treatment begins after symptoms appear for more than 5 days. Therefore, a rapid and accurate diagnosis is critical to reduce the mortality rate.
For the detection of different subtypes of influenza a virus, there are various methods, which are classified into virus isolation detection, nucleic acid detection, antigen detection, antibody detection, etc., based on the difference of detection targets. However, the above methods all require special equipment and conditions, and are not suitable for some areas where the conditions fall behind. Therefore, development of a rapid, sensitive and low-cost H1N1 virus detection product is imperative, which can promote earlier and wider discovery of H1N1 infection, reduce occurrence of severe cases and reduce the fatality rate.
In summary, development of monoclonal antibodies to H1N1 influenza virus for rapid and sensitive detection methods is urgent. Based on the background, the project selects nucleoprotein as target antigen, adopts fusion hybridoma technology to establish hybridoma cell line for stably secreting anti-nucleoprotein monoclonal antibodies, and prepares, purifies and identifies the monoclonal antibodies in a large quantity. The successful acquisition of the monoclonal antibody lays a material foundation for establishing a novel H1N1 influenza virus disease diagnosis method, namely diagnosis based on immunological technology. And plays an important role in researching the pathogenesis, prognosis, curative effect judgment and the like of the diseases.
The invention uses hybridoma cell technology. This technique fuses B lymphocytes of immunized mice with myeloma cells to establish a hybridoma cell line that secretes homogeneous antibodies, also known as a monoclonal antibody technique. The technology relates to a series of methods such as animal immunization, cell culture, cell fusion, cell clone culture, immunoassay and the like.
Disclosure of Invention
The invention aims to provide an anti-H1N 1 influenza virus nucleoprotein monoclonal antibody which can identify H1N1 influenza virus. The subtype of the monoclonal antibody is IgG2a and kappa type, named ZJU-NP-A1, and can specifically recognize nucleoprotein of influenza virus.
The sequence is as follows:
SEQ ID No.1
Heavy chain:DNA sequence(360bp)
Signal sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
GACGTGAGGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTTACTATACCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACCATTAGTTATGGTGATAGTTCGACCTTCTATCCAGACAGTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCGAGAACACCCTGTACCTGGTAATGACCAGTCTGAAGTCTGAGGACACAGCCATGTATTACTGTACAAGAGCGTCTTTCGACGGGGCCGCCTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA
SEQ ID No.2
Heavy chain:Amino acid sequence(120AA)
Signal peptide-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
DVRLVESGGGLVKPGGSLKLSCAASGFTFSYYTMSWVRQTPEKRLEWVATISYGDSSTFYPDSVKGRFTISRDNAENTLYLVMTSLKSEDTAMYYCTRASFDGAAWFAYWGQGTLVTVSA
SEQ ID No.3
Light chain:DNA sequence(339bp)
Signal sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
GACATTGTGATGACACAGTCTCCACCCTCCCTGAGTGTGTCAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAGTAGTGGAAATCAAAAGAACTACTTGGCCTGGTACCAGCAGAAACCAGGGCAGCCTCCTAAACTGTTGATCTACGGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACCGATTTCACTCTCACCATCAGCAGTGTGCTGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATGAGCATAGTTATCCGTATACGTTCGGAGGGGGGATCAAGCTGGAAATAAAA
SEQ ID No.4
Light chain:Amino acid sequence(113AA)
Signal peptide-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
DIVMTQSPPSLSVSAGEKVTMSCKSSQSLLSSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFTGSGSGTDFTLTISSVLAEDLAVYYCQNEHSYPYTFGGGIKLEIK
The second object of the invention is to provide a preparation method of an anti-H1N 1 influenza virus nucleoprotein monoclonal antibody, which is realized by the following steps and technical schemes:
(1) Immunization of animals: BALB/C mice at 6 weeks of age were selected and immunized with purified H1N1 influenza virus nucleoprotein.
(2) Culture of mouse myeloma cells: mouse myeloma cells SP2/0 were cultured and maintained in a good growth state for cell fusion.
(3) Cell fusion: polyethylene glycol fusion is used. BALB/C mouse peritoneal macrophages were used as feeder cells, and the day before fusion, BALB/C mouse peritoneal macrophages were inoculated into 96-well plates and cultured for one day in hypoxanthine-guanine-phosphoribosyl transferase medium containing 20% bovine serum. The mice prepared in (1) were sacrificed and spleen lymphocytes were obtained. Collecting the mouse myeloma cells in (2). The two cells were mixed and centrifuged, and then cell fusion was mediated with polyethylene glycol. The fused cells are diluted appropriately and inoculated into feeder cell culture plates for proper condition culture.
(4) Selection of hybridoma cells: the above culture was cultured in a selective medium for hypoxanthine-phosphoribosyl transferase. When the cell colony grows to a proper size, sucking the cell culture supernatant for antibody identification, and screening positive clones.
(5) Cloning of hybridoma cells: hybridoma cells were cloned by limiting dilution, and cells diluted to a certain density were inoculated into 96-well plates, so that only one cell per well grew. And taking culture supernatant from the hole for forming the cell colony, and performing an enzyme-linked immunosorbent assay to identify positive clones. Limiting dilution cloning was repeated several times until the positive porosity of the hybridoma cells reached 100%. And (3) performing antibody identification and physicochemical property analysis on the cloned hybridoma cells by amplification culture.
(6) Induction of monoclonal antibody ascites: one week before hybridoma cell inoculation, BALB/C mice were intraperitoneally injected with paraffin oil each 0.5 ml, then each was inoculated with 500 ten thousand positive hybridoma cells, ascites were collected after 10 days for centrifugation, antibody titers were determined, and monoclonal antibodies were purified.
(7) Purification of monoclonal antibodies: monoclonal antibodies in ascites were purified by Protein G affinity purification.
(8) The invention obtains a hybridoma line for generating anti-H1N 1 influenza virus nucleoprotein monoclonal antibody, namely ZJU-NP-A1, and the ZJU-NP-A1 hybridoma cell line is subjected to cloning for 5 times, and is continuously cultured for six months, and the secreted antibody is stable. The cell strain grows well after being thawed by liquid nitrogen, and the antibody secretion is not declined. The affinity of the antibody to H1N1 nucleoprotein after ZJU-NP-A1 ascites purification can reach 10 nanograms per milliliter as measured by an enzyme-linked immunosorbent assay indirect method. Analysis of monoclonal antibody immunoglobulin subtype shows that the antibody produced by this hybridoma cell is of the type IgG2a.
The invention provides a hybridoma cell for producing monoclonal antibodies, which is a mouse hybridoma cell line ZJU-NP-A1 obtained by fusing, screening, cloning, passaging and repeatedly freezing and recovering immunized BALB/C mouse spleen cells and mouse myeloma cells SP2/0, and can stably secrete the monoclonal antibodies ZJU-NP-A1 of anti-H1N 1 influenza virus nucleoprotein.
The invention also aims to provide application of the monoclonal antibody ZJU-NP-A1 in detection of H1N1 influenza virus and other different influenza virus subtypes, which is realized through immunofluorescence experiments.
The invention has the advantage of providing a monoclonal antibody for resisting H1N1 influenza virus nucleoprotein. The preparation method is simple and feasible, and more importantly, the monoclonal antibody prepared by the method can be used for various purposes, such as qualitative diagnosis of H1N1 influenza samples in clinic and laboratory.
Drawings
FIG. 1 shows immunoglobulin subtype analysis of monoclonal antibody ZJU-NP-A1.
FIG. 2 shows the affinity of monoclonal antibody ZJU-NP-A1 for detection of H1N1 influenza virus.
FIG. 3 shows the specificity of the monoclonal antibody ZJU-NP-A1 for detecting H1N1 influenza virus.
Detailed Description
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention.
Example 1 preparation of monoclonal antibodies against H1N1 influenza virus nucleoprotein
(1) Immunization of mice: for the first immunization, the purified H1N1 influenza virus nucleoprotein and the adjuvant are uniformly mixed according to the equal volume, and the total volume is 600 microliters. Each BALB/C mouse was injected intramuscularly at the inner thigh with 0.1 ml (30. Mu.g of H1N1 influenza virus nucleoprotein antigen). One needle was boosted in the same way on day 21. Micro tail blood is collected on the 35 th day for enzyme-linked immunosorbent assay measurement, the antibody titer reaches 1:128000, and then the tail vein is injected for boosting milliliter for immunization once, and cell fusion is carried out after 3 days.
(2) Culture of mouse myeloma cell SP 2/0: SP2/0 myeloma cell lines from BALB/C mice were passaged in 10% bovine serum DMEM medium and cultured in a 37℃incubator saturated with 5% carbon dioxide. Passaging is performed one day before fusion to ensure that cells enter the logarithmic phase of growth when fused.
(3) Cell fusion: BALB/C mouse peritoneal macrophages were used as feeder cells, and the day before fusion, BALB/C mouse peritoneal macrophages were inoculated into 96-well plates and cultured for one day in hypoxanthine-guanine-phosphoribosyl transferase medium containing 20% bovine serum. The spleen of the mice in the step (1) is taken the next day, spleen cells are separated by adopting a pressure water injection method, and the cells are centrifugally washed for 2 times and resuspended by using a culture solution. The SP2/0 cells in (2) were collected, centrifuged, washed 2 times and resuspended in culture medium as SP2/0 cells to be fused. Spleen lymphocytes from 1X 10 8 immunized mice were mixed with SP2/0 from 2X 10 7 mouse myeloma cells and fused under polyethylene glycol. The two cells were mixed and washed once, the supernatant was discarded by centrifugation, the cells were suspended from the wall of the flick tube, 0.9 ml of polyethylene glycol pre-warmed at 37℃was added dropwise to the cell pellet over 90 seconds, while the centrifuge tube was gently shaken, but not beaten, and allowed to stand for 1 minute, then 1 ml of serum-free DMEM was added in the 1 st minute, 2 ml of serum-free DMEM was added in the 2 nd minute, 7 ml of serum-free DMEM was added in the 3 rd minute, and 40 ml of serum-free DMEM medium pre-warmed at 37℃was gradually added in the latter 1 minute. Low speed centrifugation at 1000 rpm for 10 minutes. Then adding culture medium, inoculating to 96-well culture plate with feeder cells, and culturing in incubator.
(4) Selection of hybridoma cells: half of the culture medium (containing hypoxanthine-guanine-phosphoribosyl transferase) was changed every 4 days, and after 10 days, the culture medium containing hypoxanthine-phosphoribosyl transferase was used. The fused hybridoma cells were cultured in a selective medium containing hypoxanthine-phosphoribosyl transferase for about two weeks. And sucking the culture supernatant to perform an enzyme-linked immunosorbent assay, and screening positive clones. Positive hybridoma clones were screened using enzyme-linked immunosorbent assay. The method mainly comprises the following steps: ① 0.01 mol/L of PH9.6 carbonate buffer solution is used for diluting H1N1 nucleoprotein, the concentration is 20 nanograms per well, 0.1 milliliter per well is added to a 96-well ELISA plate, and the temperature is 4 ℃ overnight; ② Plate was washed three times with 0.01 mol/l PH7.4 phosphate buffer (tween 20); ③ Blocking with 2% bovine serum albumin in 0.01 mol/l phosphate buffer at pH7.4 for 2 hours; ④ Washing the plate simultaneously; ⑤ Adding hybridoma culture supernatant, 0.1 ml per well, and simultaneously setting positive control (immune mouse serum), negative control (SP 2/0 culture supernatant) and blank control, and reacting at room temperature for 2 hours; ⑥ washing the plate; ⑦ Adding horseradish peroxidase-labeled goat anti-mouse IgG (immunoglobulin G) diluted with 1:6000, and reacting for 1 hour at room temperature with 0.1 milliliter per hole; ⑧ washing the plate; ⑨ Adding a substrate to react for 5 minutes at room temperature in a dark place; ⑩ 2 mol/L sulfuric acid to terminate the reaction; the optical density value of the fluorescent powder is measured at 450 nanometers, and the measured value divided by the negative value is more than or equal to 2.1 to be positive.
(5) Cloning of hybridoma cells: cloning culture of hybridoma cells is carried out according to a limiting dilution method, and after hybridoma cells positive in antibody detection are selected for proper proliferation, the cells are accurately counted. The complete DMEM culture medium is diluted into 10 cell suspensions per milliliter, the cell suspensions are inoculated into 96-well culture plates of existing feeder cells, the growth condition of the cells is observed after 0.1 milliliter per well for 10 days, the antibody level in the supernatant is detected, and 5 culture wells with highest antibody titer and growing as single cloned cells are selected for limiting dilution again. The method can be repeated for a plurality of times until the detection positive rate of the monoclonal hole antibody is 100%.
(6) Inducing ascites: one week before hybridoma cell inoculation, BALB/C mice were intraperitoneally injected with paraffin oil each 0.5 ml, then each was inoculated with 5X 10 6 positive hybridoma cells, and ascites fluid was collected after 10 days to determine antibody titers.
(7) Purification of monoclonal antibodies: monoclonal antibodies in ascites were purified by affinity purification (Protein G cross-linked Sepharose). ① The ascites fluid was diluted 3-fold with cold binding buffer and the precipitate was removed at 10000 revolutions per minute Zhong Lixin minutes at 4 ℃. ② The affinity purification column preloaded with Sepharose-Protein G was washed thoroughly with 10 bed volumes of binding buffer. ③ The diluted ascites was put on a column and the flow rate was controlled to 10 drops per minute. ④ The running-through ascites is repeated for one time. ⑤ The reaction mixture was washed thoroughly with 20 bed volumes of binding buffer until the absorption at 280 nm was less than 0.01. ⑥ The bound monoclonal antibody was eluted with elution buffer at a flow rate of 10 drops per minute, and the eluate was collected in a collection tube pre-filled with 0.1 ml of potassium phosphate buffer (pH 7.9,0.5 mol per liter), 0.5ml of the antibody-containing eluate was collected per tube, and a total of 20 tubes were collected. ⑦ Absorbance of each tube of eluent was measured at 280 nm and the eluent with absorbance greater than 0.2 was collected. ⑧ The collected eluate was placed in a dialysis card and dialyzed against 0.1 mol/l of phosphate buffer at pH 7.4. The solution was changed every 6 hours and dialyzed for 24 hours. ⑨ The dialyzed antibody solution was diluted and the protein content was measured at 280 nm. ⑩ And (5) sub-packaging the purified antibody into small tubes, and placing the small tubes in a low-temperature refrigerator for standby.
(8) Subtype identification of monoclonal antibodies: the analysis was performed using a mouse monoclonal antibody immunoglobulin typing kit from Bio-Rad. Purified monoclonal antibodies were suitably diluted and tested, and the procedure was strictly according to the kit instructions. As a result of the test, the monoclonal antibody secreted by the ZJU-NP-A1 hybridoma was IgG2a, kappa type.
The results are shown in FIG. 1.
Example 2 detection of H1N1 nucleoprotein affinity Using the monoclonal antibody
The anti-H1N 1 influenza virus nucleoprotein monoclonal antibody prepared by the invention can specifically react with H1N1 nucleoprotein and has better affinity:
analysis of affinity of monoclonal antibodies using indirect ELISA method
(1) Diluting purified H1N1 or H3N2 virus nucleoprotein with coating buffer solution to 0.2 microgram/milliliter, adding 100 microliter of nucleoprotein diluent into each well of a 96-well ELISA plate, and coating overnight at 4 ℃;
(2) Washing the plate three times with 0.01 mol/L pH7.4 phosphate buffer (containing Tween 20), adding 200. Mu.L of blocking buffer to each well, and blocking at room temperature for 2 hr;
(3) Washing the sealing liquid with the phosphate buffer solution for three times;
(4) The purified ZJU-NP-A1 antibody was diluted to 10. Mu.g/ml with phosphate buffer, 200. Mu.l of diluted antibody was added to column 1 of 96-well plates, 100. Mu.l of phosphate buffer was added to columns 2-12, and the antibody was diluted 2-fold. Phosphate buffer, normal mouse serum and immunized mouse serum were used as blank control, negative control and positive control for incubation at room temperature for 2 hours;
(5) Washing the plate with phosphate buffer solution containing Tween 20 for three times, adding horseradish peroxidase-labeled goat anti-mouse secondary antibody in a ratio of 1:5000, adding 100 microliters into each hole, and incubating for 1 hour at room temperature;
(6) Washing the plate for three times by the same method, adding 100 microliters of color development liquid into each hole for developing color for 5 minutes, and taking care of light-proof reaction at room temperature;
(7) 100 microliters of stop solution was added to each well to stop the reaction, and the absorbance was measured at 450 nm with a microplate reader.
And (3) result judgment: positive was interpreted with a positive/negative (P/N) value of 2.1 or more. The detection result shows that the monoclonal antibody has better affinity with H1N1 nucleoprotein, which can reach 10 nanograms per milliliter.
The results are shown in FIG. 2.
EXAMPLE 3 detection of H1N1 nucleoprotein specificity Using the monoclonal antibody
The specificity of the monoclonal antibody was observed using immunofluorescence experiments
(1) The canine kidney passage cells are inoculated in a 24-well plate one day in advance, and the experiment is started after the cells grow to about 70%;
(2) Taking out the cell plate paved with cells, discarding culture supernatant, and washing with phosphate buffer solution once for standby;
(3) Diluting the viruses (H1N 1, H3N2, H9N2, H10N7, H6N1 and influenza B virus) with a virus diluent, infecting cells with the diluted virus diluent (the multiplicity of infection is 0.5), and culturing the infected cells at 37 ℃ under a condition of 5% carbon dioxide for two hours;
(4) Taking out the cell plate, discarding the virus liquid, washing the cells with phosphate buffer solution for 2 times, taking care to slowly add along the hole wall so as to avoid flushing down the cells, adding 200 microliter of virus culture solution into each hole after washing, and culturing for 16 hours at 37 ℃ in a 5% carbon dioxide incubator;
(5) Observing cytopathic conditions under a microscope, taking out a cell plate, discarding a culture supernatant, and washing cells with phosphate buffer solution for 2 times;
(6) 200 microliters of 4% paraformaldehyde was added to each well to fix the cells, after 30 minutes at room temperature, phosphate buffer was added and the plates were placed on a horizontal shaker and washed 3 times at 60 rpm for 3 minutes each;
(7) Preparing a cell permeation solution containing 0.5% polyethylene glycol octyl phenyl ether by using a phosphate buffer solution to permeate cells, and washing for 3 times by using the same method at room temperature for 30 minutes;
(8) Blocking with 3% bovine serum albumin solution, blocking at room temperature for 1 hr, and discarding blocking solution;
(9) Diluting ZJU-NP-A1 monoclonal antibody to 10 micrograms/milliliter by using phosphate buffer solution, setting irrelevant homotype antibody and phosphate buffer solution as homotype control and negative control, adding 200 microliters of the homotype control and the negative control into each hole, adding the phosphate buffer solution after overnight incubation at 4 ℃ and placing the plates on a horizontal shaking table for 3 times at a speed of 60 revolutions per minute, and 3 minutes each time;
(10) Diluting goat anti-mouse fluorescent secondary antibody to 5 microgram/ml with 1% bovine serum albumin solution, adding 200 microliter into each hole, incubating for 90 minutes at 37 ℃ in dark place, and washing the plate for 3 times by the method;
(11) Diluting the 4', 6-diamidino-2-phenylindole solution at a dilution ratio of 1:100, staining cell nuclei, incubating for 10 minutes at room temperature in the absence of light, and washing the plate for 3 times, wherein the method is the same as above;
(12) The experimental results were observed under a fluorescence microscope.
And (3) result judgment: green fluorescence was observed as positive. The detection result shows that the monoclonal antibody has better specificity with H1N1 nucleoprotein and has no cross reaction with other subtype influenza viruses.
The results are shown in FIG. 3.
It is to be understood that the present application has been described in conjunction with the preferred embodiments thereof, and that upon reading the foregoing, various changes and modifications may be made by one skilled in the art, and that these equivalents will fall within the scope of the application as defined in the appended claims.
Sequence listing
<110> Zhejiang university medical college affiliated first hospital
<120> Anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1 and application thereof in detection
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 360
<212> DNA
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 1
gacgtgaggc tggtggagtc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc 60
tcctgtgcag cctctggatt cactttcagt tactatacca tgtcttgggt tcgccagact 120
ccggagaaga ggctggagtg ggtcgcaacc attagttatg gtgatagttc gaccttctat 180
ccagacagtg tgaagggccg attcaccatc tccagagaca atgccgagaa caccctgtac 240
ctggtaatga ccagtctgaa gtctgaggac acagccatgt attactgtac aagagcgtct 300
ttcgacgggg ccgcctggtt tgcttactgg ggccaaggga ctctggtcac tgtctctgca 360
<210> 2
<211> 120
<212> PRT
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 2
Asp Val Arg Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Tyr
20 25 30
Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
35 40 45
Ala Thr Ile Ser Tyr Gly Asp Ser Ser Thr Phe Tyr Pro Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Glu Asn Thr Leu Tyr
65 70 75 80
Leu Val Met Thr Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Thr Arg Ala Ser Phe Asp Gly Ala Ala Trp Phe Ala Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ala
115 120
<210> 3
<211> 339
<212> DNA
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 3
gacattgtga tgacacagtc tccaccctcc ctgagtgtgt cagcaggaga gaaggtcact 60
atgagctgca agtccagtca gagtctgtta agtagtggaa atcaaaagaa ctacttggcc 120
tggtaccagc agaaaccagg gcagcctcct aaactgttga tctacggggc atccactagg 180
gaatctgggg tccctgatcg cttcacaggc agtggatctg gaaccgattt cactctcacc 240
atcagcagtg tgctggctga agacctggca gtttattact gtcagaatga gcatagttat 300
ccgtatacgt tcggaggggg gatcaagctg gaaataaaa 339
<210> 4
<211> 113
<212> PRT
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 4
Asp Ile Val Met Thr Gln Ser Pro Pro Ser Leu Ser Val Ser Ala Gly
1 5 10 15
Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Ser Ser
20 25 30
Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Leu Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
85 90 95
Glu His Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Ile Lys Leu Glu Ile
100 105 110
Lys
Claims (5)
1. An anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1, wherein the subtype of the monoclonal antibody is IgG2a and kappa type, the monoclonal antibody can be specifically combined with influenza virus nucleoprotein antigen, the amino acid sequence of a heavy chain variable region of the antibody is shown as SEQ ID No.2, and the amino acid sequence of a light chain variable region of the antibody is shown as SEQ ID No. 4.
2. Use of the monoclonal antibody ZJU-NP-A1 against the influenza H1N1 virus nucleoprotein according to claim 1 for the preparation of an influenza H1N1 virus detection product.
3. The use according to claim 2, wherein the detection product detects H1N1 influenza virus by immunofluorescence and enzyme-linked immunosorbent assay.
4. The use according to claim 2, wherein the monoclonal antibody ZJU-NP-A1 specifically reacts with the nucleoprotein of the H1N1 influenza virus.
5. An H1N1 influenza virus detection product, characterized in that: comprising the anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1 according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210045301.0A CN114456262B (en) | 2022-01-13 | 2022-01-13 | Anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1 and application thereof in detection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210045301.0A CN114456262B (en) | 2022-01-13 | 2022-01-13 | Anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1 and application thereof in detection |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114456262A CN114456262A (en) | 2022-05-10 |
CN114456262B true CN114456262B (en) | 2024-06-11 |
Family
ID=81410516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210045301.0A Active CN114456262B (en) | 2022-01-13 | 2022-01-13 | Anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1 and application thereof in detection |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114456262B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115947835B (en) * | 2022-11-15 | 2023-07-28 | 杭州华葵金配生物科技有限公司 | Antibody targeting influenza B virus nucleoprotein and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012046443A (en) * | 2010-08-26 | 2012-03-08 | Fujirebio Inc | Anti-np-h289 antibody and immunoassay method using the same |
CN105339389A (en) * | 2013-05-02 | 2016-02-17 | 安奈普泰斯生物有限公司 | Antibodies directed against programmed death-1 (PD-1) |
CN113383071A (en) * | 2018-11-01 | 2021-09-10 | 亘喜生物科技(上海)有限公司 | Compositions and methods for T cell engineering |
CN113817687A (en) * | 2021-09-22 | 2021-12-21 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | Hybridoma cell strain, influenza A virus nucleoprotein monoclonal antibody and application thereof |
-
2022
- 2022-01-13 CN CN202210045301.0A patent/CN114456262B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012046443A (en) * | 2010-08-26 | 2012-03-08 | Fujirebio Inc | Anti-np-h289 antibody and immunoassay method using the same |
CN105339389A (en) * | 2013-05-02 | 2016-02-17 | 安奈普泰斯生物有限公司 | Antibodies directed against programmed death-1 (PD-1) |
CN113383071A (en) * | 2018-11-01 | 2021-09-10 | 亘喜生物科技(上海)有限公司 | Compositions and methods for T cell engineering |
CN113817687A (en) * | 2021-09-22 | 2021-12-21 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | Hybridoma cell strain, influenza A virus nucleoprotein monoclonal antibody and application thereof |
Non-Patent Citations (2)
Title |
---|
Improved sensitivity of influenza A antigen detection using a combined NP, M, and NS1 sandwich ELISA;Patumporn Jian-umpunkul等;《Journal of Virological Methods》;第185卷;第24-31页 * |
乙型流感病毒检测方法的研究进展;杨帆等;《国际检验医学杂志》;第34卷(第10期);第1258-1260页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114456262A (en) | 2022-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105087497B (en) | Hybridoma cell strain ZJEB8-01, anti-Ebola virus GP protein monoclonal antibody, and preparation and application thereof | |
EP2757111B1 (en) | Anti-human norovirus gii antibody | |
CN105112375A (en) | Hybridoma cell strain ZJED0-02, anti-Ebola virus GP protein monoclonal antibody, and preparation and application thereof | |
CN111748032A (en) | Antibody against novel coronavirus and immunoassay using the same | |
CN114456262B (en) | Anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1 and application thereof in detection | |
JP2024012473A (en) | Detection reagent or kit for detecting rs virus, and method for detecting rs virus | |
CN110144007B (en) | anti-H7N 9 avian influenza virus hemagglutinin protein monoclonal antibody ZJU79-01 and application thereof | |
CN114426576B (en) | Anti-H3N 2 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A3 and application thereof in detection | |
CN112175072B (en) | Monoclonal antibody ZJU5-01 for resisting H5 subtype avian influenza virus hemagglutinin protein and application thereof | |
CN114349852B (en) | anti-H3N 2 influenza virus hemagglutinin protein monoclonal antibody ZJU32-01 and application thereof in detection | |
CN111378628B (en) | Hybridoma cell strain secreting mycobacterium tuberculosis ESAT6 protein specific antibody, antibody and application thereof | |
CN115112885B (en) | HPV detection kit and preparation method and application thereof | |
CN102539778A (en) | Enzyme linked immunosorbent assay kit for detecting recombinant human tumor necrosis factor-alpha | |
CN112830966B (en) | anti-H6N 1 avian influenza virus hemagglutinin protein monoclonal antibody ZJU61-01 and application thereof | |
JP2023052731A (en) | Adenovirus immunoassay method and immunoassay device | |
CN112851803B (en) | Monoclonal antibody ZJU10-01 for resisting H10 subtype avian influenza virus hemagglutinin protein and application thereof | |
CN114184786A (en) | Kit for rapidly detecting human immunodeficiency virus and application thereof | |
JP6481192B2 (en) | Rapid detection of quadrature septa | |
CN114957456B (en) | Monoclonal antibody ZJU-A1A3 of influenza A virus hemagglutinin protein and application thereof in detection | |
CN114891096B (en) | Anti-H1N 1 influenza virus hemagglutinin protein monoclonal antibody ZJU11-03 and application thereof | |
CN116903731A (en) | anti-Y-series influenza B virus hemagglutinin protein monoclonal antibody 1F7 and application thereof in detection | |
CN110702913A (en) | Monoclonal antibody composition for quantitatively detecting coxiella burnetii I strain | |
CN117534750B (en) | Antibody for resisting novel coronavirus nucleocapsid protein or antigen binding fragment thereof and application thereof | |
CN116063467A (en) | anti-H10 subtype avian influenza virus hemagglutinin protein monoclonal antibody 1F3 and application thereof in detection | |
CN112724249B (en) | Monoclonal antibody ZJU9-01 for resisting H9 subtype avian influenza virus hemagglutinin protein and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |